Intraperitoneal administration of 340 kDa human plasma butyrylcholinesterase increases the level of the enzyme in the cerebrospinal fluid of rats

Neurosci Lett. 2005 Jul;383(1-2):93-8. doi: 10.1016/j.neulet.2005.03.045. Epub 2005 Apr 12.

Abstract

Human butyrylcholinesterase (BuChE) is being developed as a new therapeutic for protection against the toxicity of organophosphorus agents and cocaine. The purified BuChE consists predominantly of 340 kDa tetramers and contains less than 5% monomers and dimers. Our goal was to determine whether BuChE crosses the blood-cerebrospinal fluid (CSF) barrier. Rats were injected intraperitoneally with 1mg of purified human BuChE. Plasma BuChE activity increased nearly 400-fold, while BuChE activity in the CSF increased three-fold. Sucrose density centrifugation showed that the human BuChE molecule in the rat CSF was a tetramer. Immunoprecipitation confirmed the identity of the CSF BuChE as human BuChE. The lower amount of human BuChE in the CSF (0.04%) than of smaller proteins (0.1-1%), with respect to their levels in plasma, supports the idea that passage through the blood-CSF barrier depends on molecular size. BuChE in the CSF could serve to protect the brain from the neurotoxicity of organophosphorus pesticides and cocaine.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine / blood
  • Acetylcholine / cerebrospinal fluid
  • Animals
  • Butyrylcholinesterase / administration & dosage*
  • Butyrylcholinesterase / blood
  • Butyrylcholinesterase / cerebrospinal fluid
  • Cerebrospinal Fluid / drug effects*
  • Cerebrospinal Fluid / enzymology
  • Humans
  • Immunoprecipitation / methods
  • Injections, Intraperitoneal / methods
  • Male
  • Molecular Weight
  • Plasma / drug effects
  • Plasma / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Time Factors

Substances

  • Butyrylcholinesterase
  • Acetylcholine